Cognition Therapeutics Stock Analysis

Cognition Stock Analysis Notes

About 25.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cognition Therapeutics recorded a loss per share of 0.96. The entity had not issued any dividends in recent years. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. Cognition Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Cognition Therapeutics please contact Lisa Ricciardi at 412 481 2210 or go to https://www.cogrx.com.

Cognition Therapeutics Investment Alerts

Cognition Therapeutics Upcoming and Recent Events

Cognition Largest EPS Surprises

View All Earnings Estimates

Cognition Stock Institutional Investors

Note, although Cognition Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cognition Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.77 M.

Cognition Profitablity

Management Efficiency

Cognition Therapeutics has return on total asset (ROA) of (0.937) % which means that it has lost $0.937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0831) %, meaning that it created substantial loss on money invested by shareholders. Cognition Therapeutics' management efficiency ratios could be used to measure how well Cognition Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.77 in 2024. Return On Capital Employed is likely to drop to -2.13 in 2024. At this time, Cognition Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 962.3 K in 2024, whereas Total Assets are likely to drop slightly above 35 M in 2024.

Technical Drivers

As of the 25th of November, Cognition Therapeutics shows the Risk Adjusted Performance of (0.07), mean deviation of 4.29, and Standard Deviation of 6.3. Cognition Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cognition Therapeutics Price Movement Analysis

Cognition Therapeutics Insider Trading Activities

Cognition Therapeutics Outstanding Bonds

Cognition Therapeutics Predictive Daily Indicators

Cognition Therapeutics Forecast Models

Cognition Therapeutics' time-series forecasting models are one of many Cognition Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cognition Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cognition Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cognition shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cognition Therapeutics. By using and applying Cognition Stock analysis, traders can create a robust methodology for identifying Cognition entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cognition analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cognition analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cognition Therapeutics stock analysis indicators help investors evaluate how Cognition Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cognition Therapeutics shares will generate the highest return on investment. By understating and applying Cognition Therapeutics stock analysis, traders can identify Cognition Therapeutics position entry and exit signals to maximize returns.

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.